WHO prequalifies multi-dose RSV vaccine vial, paving the way to protecting more infants globally
The WHO has prequalified the multi-dose vial presentation of the maternal respiratory syncytial virus (RSV) vaccine, RSVpreF (ABRYSVO®).
(Recording available) IDC Partner Session at WOHC2026 - Exploring bidirectional links between respiratory viruses & non-communicable diseases
Now available to watch On Demand - IDC session at 9th World One Health Congress in Lisbon, 6 September 2026.
Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants
maternal RSVpreF vaccination was associated with 78% to 81% reduction in RSV-associated hospitalization from birth through 6 months of age, with the highest vaccine effectiveness in earliest age intervals.
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study
Participants aged 3–8 years were randomised in a 1:1 ratio to receive the quadrivalent recombinant influenza vaccine (RIV4) or quadrivalent inactivated influenza vaccine (IIV4).
Influenza Vaccine Effectiveness in School Outbreaks During a A(H3N2) Subclade K (J.2.4.1)-Dominated Season in Beijing, China, 2025–26
Vaccination provided protection despite intense transmission settings
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity
These findings demonstrate that maternal RSV vaccination generates high-quality, affinity-matured transferable antibodies that provide passive immunity to infants.
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
Real-world evidence on nirsevimab impact beyond the first season when given under universal immunisation programmes is emerging.